Knight Therapeutics (TSE:GUD) Given New C$7.45 Price Target at Stifel Nicolaus

Knight Therapeutics (TSE:GUD) had its price objective boosted by Stifel Nicolaus from C$6.25 to C$7.45 in a research report issued on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 24.17% from the stock’s current price.

A number of other brokerages also recently weighed in on GUD. Research Capitl upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Canaccord Genuity Group lowered shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. One research analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of C$7.48.

Knight Therapeutics Trading Up 0.5 %

Shares of TSE GUD traded up C$0.03 during midday trading on Tuesday, reaching C$6.00. The stock had a trading volume of 41,913 shares, compared to its average volume of 71,326. The company’s 50 day moving average price is C$5.69 and its 200 day moving average price is C$5.58. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.45. The firm has a market cap of C$606.90 million, a price-to-earnings ratio of -20.03, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insiders Place Their Bets

In related news, insider Sime Armoyan acquired 17,600 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were acquired at an average cost of C$5.48 per share, for a total transaction of C$96,488.48. Over the last quarter, insiders have sold 3,143,300 shares of company stock worth $19,733,740. Corporate insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.